A pharmacodynamic study of 5-azacytidine in the P39 cell line

Experimental Hematology

Volumn 34, Issue 1, 2006, Pages 35-43

  Khan, Rasheed ^a   Aggerholm, Anni ^b,c   Hokland, Peter ^b   Hassan, Moustapha ^a   Hellström Lindberg, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; ESTROGEN RECEPTOR; UVOMORULIN;

ARTICLE; CELL CYCLE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; METHYLATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMOTER REGION;

APOPTOSIS; AZACITIDINE; CADHERINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HUMANS; LEUKEMIA, MYELOID; METHYLATION; MYOGENIC REGULATORY FACTORS; TIME FACTORS;

EID: 30344472703     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2005.09.007     Document Type: Article

References (32)

1. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
2. M. Oosterveld, S.H. Wittebol, and W.A. Lemmens The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups Br J Haematol 123 2003 81 89
3. R. Hast, E. Hellstrom-Lindberg, and L. Ohm No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease Leukemia 17 2003 1827 1833
4. J. Yasunaga, Y. Taniguchi, and K. Nosaka Identification of aberrantly methylated genes in association with adult T-cell leukemia Cancer Res 64 2004 6002 6009
5. J. Roman-Gomez, A. Jimenez-Velasco, and J.A. Castillejo Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia Blood 104 2004 2492 2498
6. P.G. Corn, B.D. Smith, and E.S. Ruckdeschel E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia Clin Cancer Res 6 2000 4243 4248
7. A. Aggerholm, P. Guldberg, M. Hokland, and P. Hokland Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia Cancer Res 59 1999 436 441
8. T. Uchida, T. Kinoshita, and H. Nagai Hypermethylation of the p15INK4B gene in myelodysplastic syndromes Blood 90 1997 1403 1409
9. M. Daskalakis, T.T. Nguyen, and C. Nguyen Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment Blood 100 2002 2957 2964
10. D.H. Christiansen, M.K. Andersen, and J. Pedersen-Bjergaard Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia Leukemia 17 2003 1813 1819
11. B. Quesnel, G. Guillerm, and R. Vereecque Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression Blood 91 1998 2985 2990
12. H.F. Tien, J.H. Tang, and W. Tsay Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation Br J Haematol 112 2001 148 154
13. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2002 2429 2440
14. A.B. Kornblith, J.E. Herndon 2nd, and L.R. Silverman Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J Clin Oncol 20 2002 2441 2452
15. J. Gryn, Z.R. Zeigler, and R.K. Shadduck Treatment of myelodysplastic syndromes with 5-azacytidine Leuk Res 26 2002 893 897
16. L.R. Silverman, J.F. Holland, and R.S. Weinberg Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 7 Suppl 1 1993 21 29
17. P. Wijermans, M. Lubbert, and G. Verhoef Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 2000 956 962
18. E. Hellstrom-Lindberg, K.H. Robert, and G. Gahrton A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia Br J Haematol 81 1992 503 511
19. J. den Hartigh, H.C. Brandenburg, and P. Vermeij Stability of azacitidine in lactated Ringer's injection frozen in polypropylene syringes Am J Hosp Pharm 46 1989 2500 2505
20. Y.W. Cheung, B.R. Vishnuvajjala, N.L. Morris, and K.P. Flora Stability of azacitidine in infusion fluids Am J Hosp Pharm 41 1984 1156 1159
21. N. Anzai, H. Kawabata, and T. Hirama Marked apoptosis of human myelomonocytic leukemia cell line P39: significance of cellular differentiation Leukemia 8 1994 446 453
22. M. Nagai, S. Seki, and T. Kitahara A novel human myelomonocytoid cell line, P39/Tsugane, derived from overt leukemia following myelodysplastic syndrome Gann 75 1984 1100 1107
23. Z. Hassan, M. Hassan, and E. Hellstrom-Lindberg The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro Leukemia 15 2001 1240 1247
24. M. Zeschnigk, C. Lich, K. Buiting, W. Doerfler, and B. Horsthemke A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus Eur J Hum Genet 5 1997 94 98
25. S.A. Takahashi-Hyodo, E.T. Sakamoto-Hojo, and C.S. Takahashi Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis Mutat Res 431 1999 13 23
26. J.P. Issa, G. Garcia-Manero, and F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies Blood 03 2004 1635 1640
27. C.P. Steuber, J. Krischer, and T. Holbrook Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study J Clin Oncol 14 1996 1521 1525
28. A.D. Kritz, G. Raptis, C. Menendez-Botet, P. Maslak, and A. Jakubowski Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia Am J Hematol 51 1996 117 121
29. J.P. Dutcher, L. Eudey, and P.H. Wiernik Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group Leukemia 6 1992 770 775
30. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
31. G. Sciandrello, F. Caradonna, M. Mauro, and G. Barbata Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells Carcinogenesis 25 2004 413 417
32. H.M. Kantarjian, and J.P. Issa Decitabine dosing schedules Semin Hematol 42 2005 S17 S22